Reuters logo
BRIEF-Kitov Pharmaceuticals announces phase III/IV clinical trial for KIT-302 successfully meets primary endpoint
October 26, 2017 / 7:52 PM / in a month

BRIEF-Kitov Pharmaceuticals announces phase III/IV clinical trial for KIT-302 successfully meets primary endpoint

Oct 26 (Reuters) - Kitov Pharmaceuticals Holdings Ltd

* Kitov pharmaceuticals announces phase iii/iv clinical trial for kit-302 successfully meets primary endpoint, and also demonstrates drug candidate improves renal function

* Kitov pharmaceuticals holdings - ‍study demonstrated that treatment with kit-302 led to a statistically significant reduction of serum creatinine​

* Kitov pharmaceuticals- ‍randomized double-blind, placebo-controlled renal function clinical trial for kit-302, met primary efficacy endpoint​

* Kitov pharmaceuticals holdings ltd - ‍anticipates completion and submission of kit-302​ report to fda by january 2018

* Kitov pharmaceuticals - ‍data from trial demonstrated kit-302 lowered systolic blood pressure a comparable amount to widely used antihypertension drug​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below